ArticleInternational journal of nanomedicine2025
PEG-Coated Ceria-Zirconia Nanoparticle Prevent Weight Gain and Obesity-Related Organ Damage Through Autophagy Flux Activation and ROS Scavenging.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Obesity is becoming a global health problem that leads to serious complications. Despite numerous efforts to lose weight, achieving this goal is very difficult. Polyethylene glycol-coated ceria-zirconia nanoparticles (PEG-CZNPs) have attracted significant attention for their antioxidant properties, but they also have another valuable ability: restoring autophagy flux. In this study, we examined the therapeutic efficacy of PEG-CZNPs against obesity-induced organ complications and investigated the associated intracellular mechanisms. Methods: Palmitate was used to establish a cellular model of obesity in HK-2 cells. An obesity mouse model was created by feeding a high-fat diet (HFD). PEG-CZNPs were successfully synthesized, and their physicochemical characteristics and antioxidant activity were confirmed. A concentration of 10 μg/mL PEG-CZNPs was used to treat HK-2 cells. For the in vivo experiment, PEG-CZNPs were administered intraperitoneally at a dose of 10 mg/kg (2 mL/kg), twice per week, with normal saline used as the vehicle control. Biochemical analysis, histological staining, and immunohistochemistry were performed on the liver, kidney and adipose tissue of the mice at 12 and 24 weeks after initiating the HFD. Results: PEG-CZNPs successfully reduced lipid droplet accumulation palmitate-treated HK-2 cells by effectively restoring impaired autophagy flux. Reactive oxygen species (ROS), inflammation, and fibrotic changes caused by palmitate were also improved by PEG-CZNP treatment. In HFD-fed mice, PEG-CZNPs significantly reduced total body weight and the weights of the liver, kidney, and adipose tissue. They notably improved glucose tolerance and serum cholesterol levels while reducing tissue lipid accumulation. Additionally, PEG-CZNP treatment alleviated inflammatory cell infiltrations and fibrotic changes in the liver, kidney, and adipose tissue of HFD-fed mice. Autophagy flux was significantly enhanced, and ROS levels decreased in the tissue following PEG-CZNP treatment. Conclusion: PEG-CZNPs alleviated obesity-induced organ damage by decreasing intracellular lipid accumulation through the restoration of autophagy flux and ROS-scavenging activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.